巨噬细胞激活因子存在于卵巢癌患者的腹水中并具有活性。
A macrophage activating factor is present and active in the ascitic fluid of patients with ovarian cancer.
作者信息
Kaneko M, Nishida M, Iwasaki H
出版信息
J Cancer Res Clin Oncol. 1985;110(2):131-5. doi: 10.1007/BF00402726.
Abstract
Morphological and functional changes in human monocytes and peritoneal macrophages from six patients with ovarian cancer were studied. The surface architecture of exudate macrophages from ascitic fluid have already been shown to exhibit extensive spreading and ruffled membranes. Consequently, peripheral monocytes from the patients were cultured with ascitic fluid from the same individuals. They gradually displayed active membrane pseudopodia, thorn-like processes and petal-like ruffles after 2 h to 4 h of cultivation. Adherent peritoneal macrophages from the patients demonstrated increased consumption of glucose. These results suggest a macrophage activating factor (MAF) exists in ascitic fluid in patients with ovarian cancer which plays an initial role in the change of monocytes into macrophages.
摘要
对6例卵巢癌患者的人单核细胞和腹腔巨噬细胞的形态学和功能变化进行了研究。来自腹水的渗出性巨噬细胞的表面结构已显示出广泛的铺展和皱襞膜。因此，将患者的外周单核细胞与来自同一患者的腹水一起培养。培养2至4小时后，它们逐渐显示出活跃的膜伪足、刺状突起和花瓣状皱襞。患者的贴壁腹腔巨噬细胞显示出葡萄糖消耗增加。这些结果表明卵巢癌患者腹水中存在巨噬细胞活化因子（MAF），其在单核细胞向巨噬细胞的转变中起初始作用。
相似文献
1
A macrophage activating factor is present and active in the ascitic fluid of patients with ovarian cancer.巨噬细胞激活因子存在于卵巢癌患者的腹水中并具有活性。
J Cancer Res Clin Oncol. 1985;110(2):131-5. doi: 10.1007/BF00402726.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
3
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
4
Monoclonal antibodies against native ovarian tumor cells: specificity and characterization of the antigen. A preliminary report.抗天然卵巢肿瘤细胞的单克隆抗体：抗原的特异性及特性。初步报告。
J Cancer Res Clin Oncol. 1995;121(7):387-92. doi: 10.1007/BF01212943.
5
Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.良性或恶性卵巢肿瘤患者白细胞介素-1β和肿瘤坏死因子-α的产生
J Cancer Res Clin Oncol. 1991;117(6):587-92. doi: 10.1007/BF01613293.
6
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
7
Blood biomarkers for the non-invasive diagnosis of endometriosis.用于子宫内膜异位症无创诊断的血液生物标志物。
Cochrane Database Syst Rev. 2016 May 1;2016(5):CD012179. doi: 10.1002/14651858.CD012179.
8
Perioperative nutrition interventions for women with ovarian cancer.卵巢癌女性的围手术期营养干预措施。
Cochrane Database Syst Rev. 2013 Sep 11;2013(9):CD009884. doi: 10.1002/14651858.CD009884.pub2.
9
Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.乳腺癌和卵巢癌患者胸腹水Her2/neu基因扩增与蛋白过表达的联合检测
J Cancer Res Clin Oncol. 2010 Sep;136(9):1389-400. doi: 10.1007/s00432-010-0790-2. Epub 2010 Mar 9.
10
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果：来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
引用本文的文献
1
Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.建立人腹膜腔器官型培养模型模拟卵巢癌早期播散。
Adv Exp Med Biol. 2021;1330:75-94. doi: 10.1007/978-3-030-73359-9_5.
2
Glycation of calmodulin binding domain of iNOS may increase the chance of occurrence of tuberculosis in chronic diabetic state.诱导型一氧化氮合酶钙调蛋白结合域的糖基化可能会增加慢性糖尿病状态下结核病的发生几率。
Bioinformation. 2011;7(7):324-7. doi: 10.6026/97320630007324. Epub 2011 Dec 10.
本文引用的文献
1
Production of an antibody against guinea pig MIF. III. Biological activity of MIF recovered from immunoadsorbent column chromatography.抗豚鼠巨噬细胞移动抑制因子抗体的制备。III. 从免疫吸附柱层析回收的巨噬细胞移动抑制因子的生物活性。
Cell Immunol. 1981 Jun;61(1):165-75. doi: 10.1016/0008-8749(81)90363-4.
2
The mechanism of macrophage activation induced by Ca2+ ionophore.钙离子载体诱导巨噬细胞活化的机制。
Cell Immunol. 1983 Feb 1;75(2):242-54. doi: 10.1016/0008-8749(83)90323-4.
3
The mechanism of cell surface changes of guinea pig macrophages activated with purified migration inhibitory factor/macrophage activation factor.用纯化的迁移抑制因子/巨噬细胞激活因子激活的豚鼠巨噬细胞的细胞表面变化机制。
Cell Immunol. 1982 Sep 15;72(2):231-8. doi: 10.1016/0008-8749(82)90471-3.
4
In vitro approaches to the mechanism of cell-mediated immune reactions.细胞介导免疫反应机制的体外研究方法。
Adv Immunol. 1971;13:101-208. doi: 10.1016/s0065-2776(08)60184-4.
5
Defective bactericidal activity of monocytes in fatal granulomatous disease.致命性肉芽肿病中单核细胞杀菌活性缺陷
Blood. 1969 Jun;33(6):813-20.
6
Changes in cellular enzyme levels and extracellular release of lysosomal acid hydrolases in macrophages exposed to group A streptococcal cell wall substance.暴露于A组链球菌细胞壁物质的巨噬细胞中细胞酶水平的变化及溶酶体酸性水解酶的细胞外释放。
J Exp Med. 1974 May 1;139(5):1262-82. doi: 10.1084/jem.139.5.1262.
7
Activation in vitro of mouse macrophages by syngeneic, allogeneic, or xenogeneic lymphocyte supernatants.同基因、异基因或异种淋巴细胞上清液对小鼠巨噬细胞的体外激活作用。
J Natl Cancer Inst. 1975 Nov;55(5):1159-63. doi: 10.1093/jnci/55.5.1159.
8
9
Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators.人巨噬细胞对肿瘤细胞的细胞毒性。人淋巴细胞介质的增强作用。
J Clin Invest. 1979 May;63(5):977-84. doi: 10.1172/JCI109398.
10
Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.脂质体包裹的淋巴因子激活小鼠巨噬细胞的杀肿瘤特性。
Cancer Res. 1979 Mar;39(3):881-92.
Zotero 插件